148 related articles for article (PubMed ID: 29158079)
21. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
Locke JA; Pond GR; Sonpavde G; Necchi A; Giannatempo P; Paluri RK; Niegisch G; Albers P; Buonerba C; Di Lorenzo G; Vaishampayan UN; North SA; Agarwal N; Hussain SA; Pal S; Eigl BJ
Clin Genitourin Cancer; 2016 Aug; 14(4):331-40. PubMed ID: 26589729
[TBL] [Abstract][Full Text] [Related]
23. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Sonpavde GP; Mariani L; Lo Vullo S; Raggi D; Giannatempo P; Bamias A; Crabb SJ; Bellmunt J; Yu EY; Niegisch G; Vaishampayan UN; Theodore C; Berthold DR; Srinivas S; Sridhar SS; Plimack ER; Rosenberg JE; Powles T; Galsky MD; Necchi A
J Urol; 2018 Dec; 200(6):1207-1214. PubMed ID: 30012366
[TBL] [Abstract][Full Text] [Related]
24. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
27. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
[TBL] [Abstract][Full Text] [Related]
28. [Vinflunine: still an option for patients with advanced urothelial carcinoma following immune-checkpoint inhibitors?].
Banna GL; Rundo F; Lipari H; Di Quattro R; Urzia V; Libra M; Malatino L
Recenti Prog Med; 2019 Dec; 110(12):615-618. PubMed ID: 31909764
[TBL] [Abstract][Full Text] [Related]
29. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
[TBL] [Abstract][Full Text] [Related]
30. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
Sengeløv L; Kamby C; Geertsen P; Andersen LJ; von der Maase H
Cancer Chemother Pharmacol; 2000; 46(5):357-64. PubMed ID: 11127939
[TBL] [Abstract][Full Text] [Related]
33. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
34. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
35. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
36. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
Vassilakopoulou M; de la Motte Rouge T; Colin P; Ouzzane A; Khayat D; Dimopoulos MA; Papadimitriou CA; Bamias A; Pignot G; Nouhaud FX; Hurel S; Guy L; Bigot P; Roumiguié M; Rouprêt M;
Cancer; 2011 Dec; 117(24):5500-8. PubMed ID: 21638278
[TBL] [Abstract][Full Text] [Related]
37. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy.
Abe T; Minami K; Harabayashi T; Sazawa A; Chiba H; Kikuchi H; Miyata H; Frumido J; Matsumoto R; Osawa T; Junji I; Tango M; Satoshi C; Tomoshige A; Masashi M; Naoto M; Kunihiko T; Satoru M; Murai S; Shinohara N
Jpn J Clin Oncol; 2020 Feb; 50(2):206-213. PubMed ID: 31665467
[TBL] [Abstract][Full Text] [Related]
39. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D; Giannatempo P; Marandino L; Pierantoni F; Maruzzo M; Lipari H; Banna GL; De Giorgi U; Casadei C; Naglieri E; Buti S; Bersanelli M; Stellato M; Santini D; Vignani F; Roviello G; Veccia A; Caffo O; Losanno T; Calabrò F; Mucciarini C; Pignata S; Necchi A; Maio MD;
Clin Genitourin Cancer; 2022 Apr; 20(2):155-164. PubMed ID: 35000876
[TBL] [Abstract][Full Text] [Related]
40. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
